Mass photometry community comes together in Boston, MA

The mass photometry user meeting took place this year on the US East Coast, bringing together a community of scientists from biopharma and academia to share knowledge and discuss the latest advancements in the field of mass photometry.

Comparing analytical approaches for AAV characterization

AAV sample characterization is a critical step in research, development and manufacturing processes of gene therapies involving these viral vectors (Figure 1). There are several analytical approaches available to assess critical quality attributes (CQAs) for AAV samples, such as capsid content (empty/full ratios) and titer.

Comparing mass photometry and CDMS for AAV analysis

Assessing AAV capsid content is critical for AAV research, development and production. There is an urgent need for reliable techniques that can characterize AAV samples efficiently and accurately, particularly when AAV sample loading shows a high level of heterogeneity [1].

The hows, whats and whys of automated mass photometry

The release of the TwoMPAuto in early 2022 represents an important improvement in the capabilities of Refeyn’s mass photometers. And like with any new product, there are some questions that frequently come up about how it works and what it can do.

Studying protein-DNA interactions with mass photometry

The study of protein-DNA interactions feeds into understanding the mechanisms of DNA replication, repair and transcription, gene expression, and the packaging of chromosomal DNA [1]. Now, a relatively new way to study protein-DNA interactions is entering the analytical toolbox: mass photometry.

How to study membrane proteins with mass photometry

The biologically important membrane proteins remain a challenging target for structural and functional studies, despite recent advances in biomolecular characterization capabilities. This is due to intrinsic difficulties in expressing, purifying and preparing membrane proteins for analysis while preserving their structure and activity.